<DOC>
	<DOCNO>NCT00050596</DOCNO>
	<brief_summary>The primary objective study determine safety activity multiple dose MDX-010 patient hormone-refractory prostate cancer ( HRPC ) , determine safety activity profile single dose cytotoxic chemotherapy ( docetaxel ) combination MDX-010</brief_summary>
	<brief_title>Comparison Study MDX-010 ( CTLA-4 ) Alone Combined With Docetaxel Treatment Patients With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Clinical diagnosis adenocarcinoma prostate . Metastatic prostate cancer ( positive bone scan measurable disease ) . Progressive disease androgen deprivation . No prior chemotherapy immunotherapy ( tumor vaccine , cytokine , growth factor give control prostate cancer ) . Other prior malignancy , except adequately treat basal squamous cell skin cancer superficial bladder cancer , cancer patient diseasefree great equal 5 year . Previous occurrence autoimmune disease . Active infection require therapy include HIV chronic hepatitis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>